Latest Posts

• Bio Roundup: Pelosi’s Reveal, Alder’s Deal, Biogen’s Fails & More

  Boston, San Francisco, and a few other metro areas might dominate the US life sciences, but some weeks, all bio-related eyes are on the nation’s capital. Health concerns about vaping continue to mount, and the feds could get involved. Meanwhile, try... Read more »

  Alex Lash9/20/19

• Pelosi, Dems Unveil Price Plan: Are 25 Drugs Enough for Negotiation?

  With the 2020 election just over a year away, House Speaker Nancy Pelosi (D-CA) has unveiled the Democratic Party’s answer to public discontent over high prescription drug prices.

  A preview of the plan was leaked last week. Today’s announcement doesn’t... Read more »

  Alex Lash9/19/19

• WI Watchlist: MSI Data, Cellular Dynamics, WARF, Redox, & More

  It’s time to catch up on recent news in Wisconsin’s innovation community. Read on for details.

  —MSI Data, a Milwaukee-based business that develops software for organizations in the equipment distribution and service contractor industries, said it received an investment... Read more »

  Jeff Buchanan9/18/19

• Why Menlo Ventures Backed Construction Tech Firm Fieldwire

  [Corrected 9/17/2019, 8:58 a.m, and 9/18/19, 4:53 p.m. See below.] Fieldwire, whose mobile app helps builders and construction crews coordinate their work, announced today it has lined up a total of $33.5 million across two newly disclosed fundraising... Read more »

  Bernadette Tansey9/16/19

• Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More

  For decades, advanced lung cancer was a quick death sentence. That’s no longer a given, thanks in part to the arrival of immunotherapy. If a medical meeting in Barcelona this week was any indication, more help could be on the... Read more »

  Ben Fidler9/13/19

• Booming CS Demand Brings Ex-Acquia CEO Back to His UW Roots

  Tom Erickson was ready to retire to Australia. But then the Wisconsin native and veteran technology executive got an offer from his alma mater that he decided he couldn’t pass up.

  This month, the University of Wisconsin-Madison named Erickson founding director... Read more »

  Jeff Bauter Engel9/13/19

• After First Look at House Drug Plan, Stocks Rise Slightly

  The first details of the long-awaited House Democrat plan to lower drug prices leaked out Monday night, with elements that have long been anathema to the biopharma industry and its supporters in Washington.

  While the world digested the details Tuesday, however,... Read more »

  Alex Lash9/10/19

• Herceptin Inventors, Immunology Pioneers Take Home 2019 Lasker Awards

  This year’s Lasker Awards, the US’s most prestigious biomedical honor, are going to five scientists whose work led to a critical breast cancer treatment and significant basic research advances that have helped pave the way for immunotherapy.

  H. Michael Shepard, Dennis... Read more »

  Ben Fidler9/10/19

• At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More

  The treatment landscape for lung cancer has shifted significantly over the past few years, and more changes could be on the way. At the World Conference on Lung Cancer in Barcelona this weekend a number of drug makers trotted out... Read more »

  Ben Fidler9/9/19

• Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone

  Being first to market with a new type of drug brings advantages. The first mover sets the bar for what physicians, payers, and patients can expect of that medicine and how much it costs. It grabs market share that followers have... Read more »

  Frank Vinluan9/6/19

• WI Watchlist: Epic, Frontdesk, Shine, StartingBlock Madison & More

  With summer coming to a close, it’s time to catch up on recent happenings in Wisconsin’s innovation clusters. Read on for details.

  —Epic Systems, the electronic medical records giant, unveiled several new products at its annual Users Group Meeting held at... Read more »

  Jeff Bauter Engel9/6/19

• With FDA’s Eye on JAK Drugs, Concert Moves One Ahead For Hair Loss

  Despite the safety concerns that have recently emerged for class of drugs known as JAK inhibitors, their reach continues to grow. The latest example comes from Concert Pharmaceuticals, which is racing the drug giant Pfizer to develop a medicine for a... Read more »

  Ben Fidler9/3/19

• Robocalls Crowd Out Real Business Calls. This Startup Has an Answer.

  The ways in which robocallers try to dupe us are becoming almost as plentiful as the frequency of the calls.

  An unknown phone number was once all scammers needed to trick the average person into picking up the call. Now,... Read more »

  David Holley8/30/19

Load More News ›

• Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More

  You might be camping, barbecuing, or sleeping on Monday. It’s Labor Day, after all. But in Paris, this cardiologist will be in a conference center, walking an audience through a slide deck packed with Phase 3 data for a new cholesterol-lowering... Read more »

  Alex Lash8/30/19

• $5.8B for Nothing: AbbVie Shelves Stemcentrx Drug After Latest Flop

  AbbVie has officially waved the white flag on the cancer drug that triggered its $5.8 billion buyout of Stemcentrx a few years ago.

  North Chicago, IL-based AbbVie (NYSE: ABBV) said that rovalpituzumab tesirine, or Rova-T, failed another clinical trial—this time... Read more »

  Ben Fidler8/29/19

• New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)

  [Updated 8/26/19, 10:30am. See below.] Remember when the new wave of expensive cholesterol-lowering drugs—known as PCSK9 inhibitors—was supposed to give the healthcare system a financial heart attack?

  Far from it. Four years after approval the two PCSK9 blockers... Read more »

  Alex Lash8/26/19

• Why Amazon’s Ascent Spells Bad News for Mall Food Courts

  The increasing popularity of Amazon’s annual Prime Day, Cyber Monday, and other online shopping-themed occasions is one of many indicators more Americans are relying on mobile devices and computers, not malls, to shop.

  It’s no secret the so-called “Amazon effect,” a... Read more »

  Jeff Buchanan8/23/19

• Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More

  Biotech news tends to slow down in August but the past seven days have been busy for regulatory decisions. Three drugs and two devices won FDA nods.

  Not all companies were as fortunate. Several biotechs reported failed clinical trials or unfavorable... Read more »

  Frank Vinluan8/23/19

• Ford’s Autonomic Connects EV Maker Ayro to Its Mobility Cloud

  Ford subsidiary Autonomic today announced a step forward in its drive to expand the online mobility hub it built to manage digital interactions among cars, drivers, fleets, service providers, and auto manufacturers—including Ford’s rivals.

  Palo Alto, CA-based Autonomic signed up Ayro... Read more »

  Bernadette Tansey8/21/19

• Bio Roundup: Zolgensma Fallout, Duchenne Redux, Ebola Boost & More

  We learned last week that the FDA was investigating Novartis for manipulating animal data related to its $2 million-a-dose gene therapy Zolgensma. The activity took place at AveXis, the firm Novartis bought for $8.7 billion in 2018, and Novartis reportedly... Read more »

  Alex Lash8/16/19

• Will Porsche Fans Ever Live in a Driverless World? Porsche Says No.

  Imagine the transportation future 20 years from now. Here’s one way things could roll on a weekday: Many of us get picked up at home by a sturdy, standardized, driverless car that will also scoop up a few of our neighbors... Read more »

  Bernadette Tansey8/16/19

• Four New Drugs Are Around the Corner. Here’s What You Need to Know.

  [Updated, 3:40 pm ET, see below] The Food and Drug Administration approved 59 new drugs last year, a record for the agency which over the years has swung back and forth between tight control and leniency. We are in... Read more »

  Ben Fidler8/15/19

Load More News ›

• WI Watchlist: AmFam, Venture Investors, Understory, Gener8tor & More

  It’s time to catch up on some recent headlines from Wisconsin’s innovation clusters:

  —Venture Investors and American Family Ventures are making progress on raising new venture funds. Madison-based Venture Investors has closed on $73.1 million for its latest fund, and... Read more »

  Jeff Bauter Engel8/14/19

• Bio Roundup: Surprise News, a Gene Therapy Mess & a CAR-T Step

  Gene therapy has become one of the hottest fields in biomedicine, with two treatments approved in the US already and several more on the way. But surprise news this week regarding Zolgensma, the recently approved spinal muscular atrophy treatment, cast... Read more »

  Ben Fidler8/9/19

• AIQ Solutions Hits On $3.2M to Pinpoint Drug-Resistant Tumors

  Many companies developing artificial intelligence software for healthcare are trying to improve doctors’ ability to diagnose disease. Fewer emerging healthcare AI businesses are focused on what happens after a diagnosis, aiming to figure out how treatments are working.

  One of them,... Read more »

  Jeff Bauter Engel8/7/19

• Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More

  [Corrected 12:55 p.m. ET. See below.] Acquisitions made Pfizer what it is today: the world’s biggest drug maker measured by revenue. But as the company maps its future, CEO Albert Bourla is breaking some of that legacy apart.

  Blockbuster... Read more »

  Frank Vinluan8/2/19

• White House Floats Canadian Import Plan But Excludes Many Costly Drugs

  [Updated, 6:18 p.m. ET. See below.] The Trump administration unveiled Wednesday a long-awaited plan to import cheaper medications from Canada and other countries.

  The US Department of Health and Human Services says the two proposals are part of the... Read more »

  Frank Vinluan7/31/19

• Mark Levin Named Xconomy’s 2019 Lifetime Achievement Award Winner in Boston

  We at Xconomy are excited to announce that we are honoring Mark Levin, co-founder and partner at Third Rock Ventures, with our 2019 Lifetime Achievement Award in Boston. The award recognizes Levin’s extensive contributions to the biotech industry and to the... Read more »

  Angela Shah7/31/19

• Exact Sciences Buying Genomic Health in $2.8B Cancer Diagnostics Deal

  [Updated 7/29/19, 10:19 am CT. See below.] With ambitious sales goals and its stock trading at an all-time high this year, cancer diagnostics firm Exact Sciences decided to go shopping. The result is a deal announced Monday to acquire... Read more »

  Jeff Bauter Engel7/29/19

• Duchenne Advocates Start Casimir, Aiming to Capture Missing Data

  Three years ago, the FDA made one of the most polarizing decisions in its history. It approved a drug for the rare genetic disease Duchenne muscular dystrophy on the slimmest of evidence, a watershed moment that caused a highly publicized rift... Read more »

  Ben Fidler7/26/19

• Bio Roundup: Leiden’s Exit, Depression Data, a New Pricing Bill & More

  What will the legacy be of Jeff Leiden, the longtime CEO of Vertex Pharmaceuticals?

  Vertex surprised Wall Street this week by announcing Leiden’s seven-year run will end next spring. In some ways, his legacy is already written. He steered Vertex... Read more »

  Ben Fidler7/26/19

Read More Posts ›